Biopharmaceutical company Ipsen launched its newly upgraded manufacturing site in Blanchardstown in Dublin today after its recent investment of €52m to upgrade and expand its capabilities.
The enhanced site, which has a staff of 175, has already enabled Ipsen Ireland's R&D and manufacturing teams to scale their active pharmaceutical ingredient production by 10% this year compared to 2021.
The company said the investment supported the extension and acceleration of vital medicine production.
Its products helps patients suffering from both niche cancers and rare diseases in Ireland and across international markets.
Ipsen also plans a further €15m of capital investment in its Blanchardstown site between 2023 and 2026 which will facilitate continued site enhancement from a technology and sustainability perspective.
The company said this additional investment is part of its ongoing growth strategy for the Irish market as a biopharmaceutical leader providing transformative care across oncology, rare diseases and neuroscience.
Ipsen CEO David Loew said the Irish market plays an important role as part of the company's international network.
"Ipsen is committed to continued investment and innovation in Ireland to support improved care for patients across the therapeutic areas we serve - oncology, rare disease and neuroscience," the CEO said.
"This new investment in Dublin is a milestone in our ongoing journey of innovation and our growing footprint in Ireland. We hope to continue building Ipsen Ireland as an important pharmaceutical manufacturing and development site within Europe," he said
Tánaiste Leo Varadkar said the company has made a significant investment in the Dublin facility which produces treatments for patients with rare and life-limiting conditions.
"It's great to see a biopharmaceutical company which has been here for over 30 years continuing to invest and grow in Ireland, particularly when the goal is to help more patients achieve a better quality of life through its medicines," Mr Varadkar said.
